Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”

With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigat...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Norman, Gail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
TRANSLATIONAL TOOLBOX
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059004/
https://www.ncbi.nlm.nih.gov/pubmed/30062214
http://dx.doi.org/10.1016/j.jacbts.2017.11.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059004/
https://www.ncbi.nlm.nih.gov/pubmed/30062214
http://dx.doi.org/10.1016/j.jacbts.2017.11.007

Ejemplares similares